Quarterly report · Q2

Period2023-01-01 → 2023-06-30
Filed2023-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥501m2023-01-01 → 2023-06-30Cons.Net sales
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥840m2022-01-01 → 2022-06-30Cons.Net sales
Operating income−¥864m2023-01-01 → 2023-06-30Cons.Operating income
Operating income−¥312m2022-01-01 → 2022-06-30Cons.Operating income
Ordinary income−¥868m2023-01-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥306m2022-01-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥869m2023-01-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥349m2022-01-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥886m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥359m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥886m2023-01-01 → 2023-06-30Cons.Profit loss
Net income−¥359m2022-01-01 → 2022-06-30Cons.Profit loss
Total assets¥4.6bnat 2023-06-30Cons.Assets
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥5.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥453mat 2023-06-30Cons.Liabilities
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Net assets / equity¥4.1bnat 2023-06-30Cons.Net assets
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥4.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥3.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.8bnat 2021-12-31dCons.Cash and cash equivalents
Operating cash flow−¥939m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥708m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥585m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥126m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥57m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.2bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥367m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥166m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-53.812023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-21.462023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-26.532022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-25.252022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio89.9%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio84.7%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥169m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥286m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥286m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥547m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥553m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥553m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥235m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 424
ItemContextValueUnit
Income taxes deferredPrior1YTDDuration-61000JPY
Income taxes deferredCurrentYTDDuration-56000JPY
Income taxesPrior1YTDDuration9740000JPY
Income taxesCurrentYTDDuration16218000JPY
Profit lossPrior1YTDDuration-359120000JPY
Profit lossCurrentYTDDuration-885608000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-359120000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-885608000JPY
Profit lossPrior1YTDDuration-359120000JPY
Profit lossCurrentYTDDuration-885608000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-1241000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-340000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration87600000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-615000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration36662000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration25174000JPY
Other comprehensive incomePrior1YTDDuration123021000JPY
Other comprehensive incomeCurrentYTDDuration24217000JPY
Comprehensive incomePrior1YTDDuration-236098000JPY
Comprehensive incomeCurrentYTDDuration-861390000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-236098000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-861390000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration-JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration-JPY
Income before income taxesPrior1YTDDuration-349379000JPY
Income before income taxesCurrentYTDDuration-869389000JPY
Depreciation and amortization ope cfPrior1YTDDuration13604000JPY
Depreciation and amortization ope cfCurrentYTDDuration16602000JPY
Impairment loss ope cfPrior1YTDDuration42948000JPY
Impairment loss ope cfCurrentYTDDuration984000JPY
Interest income ope cfPrior1YTDDuration-57000JPY
Interest income ope cfCurrentYTDDuration-84000JPY
Dividends income ope cfPrior1YTDDuration-204000JPY
Dividends income ope cfCurrentYTDDuration-211000JPY
Interest expenses ope cfPrior1YTDDuration3063000JPY
Interest expenses ope cfCurrentYTDDuration1695000JPY
Share based compensation expenses ope cfPrior1YTDDuration24205000JPY
Share based compensation expenses ope cfCurrentYTDDuration22045000JPY
Stock issuance cost ope cfPrior1YTDDuration1434000JPY
Stock issuance cost ope cfCurrentYTDDuration4966000JPY
Foreign exchange losses gains ope cfPrior1YTDDuration-20351000JPY
Foreign exchange losses gains ope cfCurrentYTDDuration-12264000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration1125012000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-4462000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-2693000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-21386000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration-1814000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration-1962000JPY
Increase decrease in accounts payable other ope cfPrior1YTDDuration-105334000JPY
Increase decrease in accounts payable other ope cfCurrentYTDDuration-97373000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass